Nature Communications (Mar 2017)
Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis
- Anh T. Tran,
- Emma E. Watson,
- Venugopal Pujari,
- Trent Conroy,
- Luke J. Dowman,
- Andrew M. Giltrap,
- Angel Pang,
- Weng Ruh Wong,
- Roger G. Linington,
- Sebabrata Mahapatra,
- Jessica Saunders,
- Susan A. Charman,
- Nicholas P. West,
- Timothy D. H. Bugg,
- Julie Tod,
- Christopher G. Dowson,
- David I. Roper,
- Dean C. Crick,
- Warwick J. Britton,
- Richard J. Payne
Affiliations
- Anh T. Tran
- School of Chemistry, The University of Sydney
- Emma E. Watson
- School of Chemistry, The University of Sydney
- Venugopal Pujari
- Department of Microbiology, Mycobacteria Research Laboratories, Immunology and Pathology, Colorado State University
- Trent Conroy
- School of Chemistry, The University of Sydney
- Luke J. Dowman
- School of Chemistry, The University of Sydney
- Andrew M. Giltrap
- School of Chemistry, The University of Sydney
- Angel Pang
- Centenary Institute and Sydney Medical School, The University of Sydney
- Weng Ruh Wong
- Department of Chemistry and Biochemistry, University of California
- Roger G. Linington
- Department of Chemistry and Biochemistry, University of California
- Sebabrata Mahapatra
- Department of Microbiology, Mycobacteria Research Laboratories, Immunology and Pathology, Colorado State University
- Jessica Saunders
- Centre for Drug Candidate Optimisation, Monash University
- Susan A. Charman
- Centre for Drug Candidate Optimisation, Monash University
- Nicholas P. West
- School of Chemistry and Molecular Biosciences, University of Queensland
- Timothy D. H. Bugg
- Department of Chemistry, University of Warwick
- Julie Tod
- School of Life Sciences, University of Warwick
- Christopher G. Dowson
- School of Life Sciences, University of Warwick
- David I. Roper
- School of Life Sciences, University of Warwick
- Dean C. Crick
- Department of Microbiology, Mycobacteria Research Laboratories, Immunology and Pathology, Colorado State University
- Warwick J. Britton
- Centenary Institute and Sydney Medical School, The University of Sydney
- Richard J. Payne
- School of Chemistry, The University of Sydney
- DOI
- https://doi.org/10.1038/ncomms14414
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 9
Abstract
Drug resistant tuberculosis (TB) infections are emerging at a high rate, with only few therapeutic options currently available. Here, the authors report synthetic analogues of the natural product sansanmycin that target mycobacterial cell wall biosynthesis and represent potent leads for improved anti-TB treatments.
